Olema Pharmaceuticals (OLMA) Citi’s 2026 Virtual Oncology Leadership Summit summary

Company and lead asset overview

• Focused on ER-positive, HER2-negative breast cancer, aiming to improve standard of care with novel therapies.

• Lead asset palazestrant is a complete estrogen receptor antagonist, administered as a once-daily oral pill.

• Two pivotal phase III trials: OPERA-01 (monotherapy, second/third-line) and OPERA-02 (first-line combination).

• OPERA-01 results expected in fall 2024; OPERA-02 readout likely in 2028 or 2029.

• Additional clinical program OP-3136 (oral KAT6 inhibitor) in phase I/II, exploring combinations and monotherapy.

Differentiation and competitive landscape

• Palazestrant offers complete estrogen receptor antagonism, unlike partial antagonists in the class.

• Superior pharmacokinetics with high exposure and long half-life, supporting continuous receptor blockade.

• Demonstrated tolerability allows full-dose combinations with other agents without dose reductions.

• Competitive landscape includes agents like giredestrant and camizestrant; palazestrant shows unique molecular and PK advantages.

• Activity observed in both ESR1 wild-type and mutant populations, a key differentiator.

Clinical trial design and market potential

• OPERA-01 targets a substantial second/third-line market, estimated at $5B annually, with $2B for ESR1 mutant subset.

• ESR1 wild-type population remains an unmet need, with OPERA-01 designed to test both mutant and wild-type independently.

• Approval bar is a two-month median PFS improvement over standard of care; positive readout could support launch in 2025.

• Commercial infrastructure being built for US/EU launch; global launch would require a partner.

• OPERA-02 first-line trial design incorporates learnings from recent studies and may be adjusted based on evolving control arm performance.